Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Treasury Shares (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Treasury Shares for 4 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 22646.69% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, up 22646.69% year-over-year, with the annual reading at $5.6 million for FY2025, 97.9% up from the prior year.
  • Treasury Shares for Q4 2025 was $5.6 million at Century Therapeutics, down from $6.6 million in the prior quarter.
  • The five-year high for Treasury Shares was $6.6 million in Q3 2025, with the low at $24685.0 in Q3 2024.
  • Average Treasury Shares over 4 years is $1.4 million, with a median of $121248.0 recorded in 2022.
  • The sharpest move saw Treasury Shares plummeted 90.5% in 2023, then skyrocketed 26750.31% in 2025.
  • Over 4 years, Treasury Shares stood at $193031.0 in 2022, then crashed by 74.4% to $49416.0 in 2023, then plummeted by 49.77% to $24821.0 in 2024, then skyrocketed by 22646.69% to $5.6 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $5.6 million, $6.6 million, and $4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.